China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
In this study at UCLA, a national leader in the care of patients with sarcoma, researchers used a condensed five-day radiation regimen that considerably cuts down the length of treatment and the time to surgery.“Shortening the radiation therapy from five weeks to five days has been a very meaningful change for patients,” said lead author Dr. Anusha Kalbasi, assistant professor of radiation oncology in the division of molecular and cellular oncology. “Five weeks of daily treatments is a burdensome com mitment for patients. The daily back-and-forth can be expensive and time consuming, and it can really inte...
Source: UCLA Newsroom: Health Sciences - February 13, 2020 Category: Universities & Medical Training Source Type: news

Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer
SAN DIEGO, Feb. 13, 2020 -- (Healthcare Sales & Marketing Network) -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced that a Decipher GRID mole... Diagnostics, Oncology Decipher Biosciences, Decipher GRID, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2020 Category: Pharmaceuticals Source Type: news

HRT of Menopausal Symptoms After Gynecologic Malignancy HRT of Menopausal Symptoms After Gynecologic Malignancy
This review focuses on the safety of hormone replacement therapy in women with a history of gynecologic cancer who have undergone surgery, chemotherapy, or radiation leading to early menopause.Menopause (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2020 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Out of balance - Postural control in cancer patients before and after neurotoxic chemotherapy - M üller J, Ringhof S, Vollmer M, Jäger LB, Stein T, Weiler M, Wiskemann J.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect deriving from neurotoxic chemotherapeutic agents. The underlying nerve injury can affect proprioception causing impaired postural control, gait difficulties and a higher... (Source: SafetyLit)
Source: SafetyLit - February 12, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Alternative to Alimta Coming for Mesothelioma Patients
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - February 12, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

High BMI May Cut Overall Survival in HER2 + Metastatic Breast Cancer
BMI had no impact on progression - free survival to first - line chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news

What fuels a 'domino effect' in cancer drug resistance?
(The Korea Advanced Institute of Science and Technology (KAIST)) KAIST researchers have identified mechanisms that relay prior acquired resistance to the first-line chemotherapy to the second-line targeted therapy, fueling a 'domino effect' in cancer drug resistance. Their study featured in the February 7 edition of Science Advances suggests a new strategy for improving the second-line setting of cancer treatment for patients who showed resistance to anti-cancer drugs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 11, 2020 Category: Biology Source Type: news

BrainCool AB completes recruitment in trial for FDA clearance of oral mucositis treatment
(King + Company) BrainCool AB, a world leader in medical cooling, has completed patient recruitment for testing of the Intra-Oral Cooling Device Cooral to Eliminate Oral Mucositis, one of the severest side effects of chemotherapy and radiation cancer treatments, and is on track with its De Novo 510(k) process for Market Registration in the U.S. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news

Cindy Crawford Shines a Light on the Need for Blood Donations with Give Blood to Give Time
“I was 8 years old when my brother was diagnosed with leukemia,” said Cindy Crawford. “I remember my parents coming home and telling us that. I didn’t really know what ... The post Cindy Crawford... {This is a content summary only. Click the blog post title to continue reading this post, share your comments, browse the blog and more!} (Source: Red Cross Chat)
Source: Red Cross Chat - February 10, 2020 Category: International Medicine & Public Health Authors: American Red Cross Tags: Blood American Cancer Society blood donation blood donor chemotherapy Cindy Crawford platelets whole blood Source Type: news

High-Dose Chemotherapy for Breast Cancer May Not Improve Long-Term Survival
A recent study found that patients with stage III breast cancer did not benefit from high-dose chemotherapy, nor did it impact long-term risks of major cardiovascular events. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Mayo researchers discover way to prime cancer tumors for immunotherapy
(Mayo Clinic) A cancer tumor's ability to mutate allows it to escape from chemotherapy and other attempts to kill it. So, encouraging mutations would not be a logical path for cancer researchers. Yet a Mayo Clinic team and their collaborators took that counterintuitive approach and discovered that while it created resistance to chemotherapy, it also made tumors sensitive to immunotherapy. They also found that this approach worked successfully across tumor types and individual patient genomes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2020 Category: International Medicine & Public Health Source Type: news

UCLA research could be step toward lab-grown eggs and sperm to treat infertility
A new study on how and when the precursors to eggs and sperm are formed during development could help pave the way for generating egg and sperm cells in the lab to treat infertility.The study, published in the journal Cell Reports, describes the way in which human stem cells evolve into germ cells, the precursors for egg and sperm cells.“Right now, if your body doesn’t make germ cells then there’s no option for having a child that’s biologically related to you,” said Amander Clark, the study’s lead author, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem...
Source: UCLA Newsroom: Health Sciences - February 6, 2020 Category: Universities & Medical Training Source Type: news

When the Teenager or Young Adult Has Cancer
Adolescents and young adults are a special population of cancer patients. (Source: NYT Health)
Source: NYT Health - February 6, 2020 Category: Consumer Health News Authors: Mikkael A. Sekeres, M.D. Tags: Hospitals Chemotherapy Lymphoma Age, Chronological Cancer Leukemia Youth Doctors Source Type: news

Why taking antioxidants during chemotherapy for breast cancer could be counterproductive
Canadians spend an estimated $3 billion a year on vitamin supplements. And while the medical community has long questioned their usefulness in otherwise healthy people, a new study adds to the research that suggests taking supplements during cancer treatment could be counterproductive. (Source: CBC | Health)
Source: CBC | Health - February 6, 2020 Category: Consumer Health News Tags: News/Health Source Type: news

Botanical drug is shown to help patients with head and neck cancers
In this study, UCLA researchers found that when APG-157 is taken through oral mucosal absorption, patients have high levels of curcumin circulating in their blood and absorbed by cancer tissues.METHODUCLA researchers conducted the study of APG-157 comparing 12 people who had oral and oropharyngeal cancer with a control group of 13 people who did not have cancer. The reason both the people with cancer and without cancer were part of the study was to show that the drug was not toxic to either people with cancer or those without cancer.The medication was given each hour for three hours and was delivered as a lozenge that slow...
Source: UCLA Newsroom: Health Sciences - February 6, 2020 Category: Universities & Medical Training Source Type: news

CT Signature Predicts Survival, Chemotherapy Benefit in Gastric Cancer CT Signature Predicts Survival, Chemotherapy Benefit in Gastric Cancer
A deep-learning signature based on preoperative CT images predicts survival and the benefit of adjuvant chemotherapy in patients with gastric cancer, researchers report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 5, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Medics in Glasgow probe heart risk side effects of chemotherapy
A major study will investigate the cause of heart problems developed after taking modern cancer drugs. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 3, 2020 Category: Consumer Health News Source Type: news

AHA News: Millions Are Learning to Live With Heart Failure
MONDAY, Feb. 3, 2020 (American Heart Association News) -- It was almost six years to the day after Aimee Rodriguez-Zepeda completed her chemotherapy that doctors listened to her heart and gave her the bad news. " I was exhausted, " she said. " They... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 3, 2020 Category: General Medicine Source Type: news

Cape Breton cancer patient fed up with parking tickets handed out during chemo
A Cape Breton cancer patient says he's had enough with the parking tickets he's received while getting chemotherapy. (Source: CBC | Health)
Source: CBC | Health - February 3, 2020 Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news

AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL) Represents thir... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 31, 2020 Category: Pharmaceuticals Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

As of January 1, 2020, the cancer industry has now killed 20 million people around the world since the year 2000
(Natural News) If you’re curious how many people are dying from things that the government claims are “safe and effective,” look no further than the Pharma Death Clock website, which explains that more than 20 million people have died from chemotherapy alone since the year 2000. As it turns out, the chemical cocktails manufactured by Big... (Source: NaturalNews.com)
Source: NaturalNews.com - January 31, 2020 Category: Consumer Health News Source Type: news

Less chemotherapy may have more benefit in rectal cancer
(University of Colorado Anschutz Medical Campus) GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2020 Category: Cancer & Oncology Source Type: news

Would you refuse lifesaving cancer therapy if it meant losing your hair?
Research suggests 8 per cent, one in 12, refuse or delay potentially life-saving treatment due to the psychological distress of losing their hair due to chemotherapy for cancer treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - January 28, 2020 Category: Consumer Health News Source Type: news

ONCOS-102 Shows Promise in Combination Mesothelioma Treatment
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - January 27, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Patients suffer invasive treatments for harmless cancers
(Bond University Australia) Australians are increasingly being diagnosed with cancers that will do them no harm if left undetected or untreated, exposing them to unnecessary surgeries and chemotherapy, says a new study published online today in the Medical Journal of Australia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 26, 2020 Category: Cancer & Oncology Source Type: news

My Father ’s Passport
Against the advice of his oncologist, my father was unplugging himself, demanding to be released not only from the hospital, but from life as we know it. It felt like a victory. (Source: NYT Health)
Source: NYT Health - January 23, 2020 Category: Consumer Health News Authors: Christine Hemp Tags: Hospitals Chemotherapy Death and Dying Families and Family Life Road Trips Source Type: news

Dasatinib Yields Superior Results Compared to Imatinib in Pediatric Patients with ALL
Combined with intensive chemotherapy, the next-generation inhibitor provided excellent results in pediatric patients with Philadelphia chromosome-positive ALL, leading to changes in how this population is treated. (Source: CancerNetwork)
Source: CancerNetwork - January 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Male fertility after chemotherapy: New questions raised
(Institut national de la recherche scientifique - INRS) Professor Delb è s, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma. Their results, recently published in the journal Plos One, raise important questions about male fertility and the long-term quality of life of cancer survivors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2020 Category: Cancer & Oncology Source Type: news

Dasatinib Tops Imatinib for Ph + Acute Lymphoblastic Leukemia
Four - year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 21, 2020 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Pharmacy, Journal, Source Type: news

Plinabulin Continues to Show Promise for Treating Chemotherapy-Induced Neutropenia
The drug has demonstrated the ability to reduce neutropenia induced by chemotherapy without affecting bone marrow or blood-G-CSF levels. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Celecoxib Added to Concurrent Chemoradiation Not Effective for Patients with NSCLC
Although concurrent chemotherapy and radiation is considered standard care, treatment of locally advanced NSCLC continues to be challenging, leading researchers to search for patients who may benefit from the addition of cyclooxygenase 2 inhibitors. (Source: CancerNetwork)
Source: CancerNetwork - January 16, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere
Neoadjuvant systemic therapy can facilitate breast conservation in certain women with stage II and III operable breast cancer. But compared to other countries, significantly fewer women in the United States make such a choice.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab. (Source: World Pharma News)
Source: World Pharma News - January 15, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

National Prostate Cancer Audit Report - Annual Report 2019
This is the first national audit report on process and outcome measures from all aspects of the care pathway for men with prostate cancer. The information presented compares prostate cancer services locally and nationally, including access to chemotherapy. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 15, 2020 Category: Consumer Health News Source Type: news

Antioxidant Supplement Use During Chemo May Increase Risk for Breast Cancer Recurrence
This study provides data for consideration when discussing with patients the use of dietary supplements while undergoing chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - January 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

New nanoparticle therapy offers potential new treatment for aggressive breast cancer
(University of Maryland School of Medicine) Researchers developed a new nanoparticle drug formulation that targets a specific receptor on cancer cells, and appears to be more effective than a standard nanoparticle therapy currently on the market to treat metastatic breast cancer. The study, published today in the journal Science Advances, found that the new 'DART' nanoparticles bypass healthy cells and tissues and bind to tumor cells, dispersing evenly throughout the tumor while releasing the chemotherapy drug paclitaxel. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2020 Category: Cancer & Oncology Source Type: news

Charlestown Cancer Survivor Hopes Story Inspires Others To Get Screened
BOSTON (CBS) – January is cervical cancer awareness month and Kate Weissman of Charlestown is hoping her story will inspire women to get potentially life-saving screening tests. Four years ago, she heard the words that everyone dreads – “You have cancer.” “It was devastating,” she recalls thinking of that moment alone in her apartment. “I just said to myself, I’m 30 and I’m going to die.” Weissman endured months of grueling treatment. Doctors initially thought they got it all, but the cancer turned up in her lymph nodes. So she had to go back for more treatment, a...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 14, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Syndicated CBSN Boston Syndicated Local cervical cancer Source Type: news

Researchers Find Potential New Target for Mesothelioma Treatment
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team, said the goal is reducing mesothelioma mortality with a combinational therapy that includes this new target. “These findings help us define molecular mechanisms that may be key to mesothelioma aggressiveness and progression,...
Source: Asbestos and Mesothelioma News - January 14, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

A solid vaccine for liquid tumors
(Wyss Institute for Biologically Inspired Engineering at Harvard) Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years. Chemotherapy has been the standard treatment for over 40 years, and while it often causes the cancer to go into remission, nearly half of patients experience disease relapse. Scientists at the Wyss Institute and Harvard SEAS have developed an injectable, biomaterial-based vaccine that, when combined with standard chemotherapy, caused complete and lasting recovery from and immunity against AML in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2020 Category: Cancer & Oncology Source Type: news

Tomohiro Nishijima earns The Oncologist's Young Investigator Award
(AlphaMed Press, Inc.) Tomohiro Nishijima, M.D., was awarded The Oncologist's 2nd Annual Young Investigator Award for his research on how the chemotherapy toxicity risk score may assist doctors in making treatment decisions for older patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2020 Category: Cancer & Oncology Source Type: news

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
DURHAM, N.C., Jan. 13, 2020 -- (Healthcare Sales & Marketing Network) -- Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), has been granted Orphan Drug Designation1 (ODD) by the US Food and Drug Administr... Biopharmaceuticals, Oncology, FDA Dova Pharmaceuticals, avatrombopag, Chemotherapy-Induced, Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 13, 2020 Category: Pharmaceuticals Source Type: news

Investigational drugs block bone loss in mice receiving chemotherapy
(Washington University School of Medicine) Studying mice, researchers from Washington University School of Medicine in St. Louis have found a driver of bone loss related to cancer treatment. Radiation and chemotherapy can halt cell division in bone, which results in a stress response called senescence. This process is independent of hormones that affect bone health, such as estrogen. Such bone loss can be stopped by treating the mice with either of two investigational drugs already being evaluated in clinical trials, according to the researchers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 13, 2020 Category: Cancer & Oncology Source Type: news

Study finds novel molecular therapeutic target for colon cancer
(Boston University School of Medicine) Researchers have found a way to help make chemotherapy more effective in treating colon cancer. They identified a new pathway (RICTOR/mTORC2) as a biological target for the disease. Targeted inhibition of RICTOR or the mTORC2 pathway could be used as a distinctive therapeutic opportunity with chemotherapy for treating colon cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 13, 2020 Category: Cancer & Oncology Source Type: news

As of January 1, 2020, the cancer industry has now killed 20 million people around the world since the year 2000
(Natural News) If you’re curious how many people are dying from things that the government claims are “safe and effective,” look no further than the Pharma Death Clock website, which explains that more than 20 million people have died from chemotherapy alone since the year 2000. As it turns out, the chemical cocktails manufactured by... (Source: NaturalNews.com)
Source: NaturalNews.com - January 12, 2020 Category: Consumer Health News Source Type: news

Patients With Acute Leukemias Have Increased Risk for Heart Failure, Study Shows
Researchers developed a risk score assessment to measure potential risk for chemotherapy-induced heart failure (Source: CancerNetwork)
Source: CancerNetwork - January 11, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

National Bowel Cancer Audit Annual Report 2019
This tenth report of the audit includes data on over 30,000 patients diagnosed with bowel cancer between 01 April 2017 and 31 March 2018. For the first time, indicators of return to theatre and robotic surgery are reported and the measure of adjuvant chemotherapy for stage III colon cancer is reported at trust/hospital level in England. The report discusses several key findings for care pathways, surgical care, survival, rectal cancer and National Cancer Registry data. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 10, 2020 Category: Consumer Health News Source Type: news